Literature DB >> 11005313

Modulation of the T cell receptor beta chain repertoire after heart transplantation.

K Doumaid1, P P van Miert, L M Vaessen, E B Remmerswaal, W Weimar, C J Boog.   

Abstract

BACKGROUND: In a previous study it was shown that pre-transplant blood transfusion was associated with a better clinical outcome after heart transplantation (HTx). In this study the effect of heart transplantation (HTx) on the T cell receptor V beta chain (TCRVbeta) repertoire was investigated. Therefore, we analyzed the TCRVbeta repertoire of patients after HTx to see whether a correlation with clinical outcome could be observed.
METHODS: Patients were analyzed at four different time points: pre-HTx, less than 1 month post-Htx, between 1 month and 2.5 month post-Htx and more than 2.5 months post-HTx. CD4+ and CD8+ T cells were purified from patient peripheral blood mononuclear cells (PBMC). TCR beta chain usage was analyzed semiquantitatively by Southern blot analysis.
RESULTS: HTx affected the TCRVbeta repertoire in both the CD4+ and CD8+ T cell compartments in all patients. Changes in the TCRVbeta repertoire were most pronounced within the CD8+ T cell subset. Interestingly, one patient showed modulation in TCRVbeta chain usage predominantly in the CD4+ T cell compartment.
CONCLUSIONS: Modulation of TCRVbeta chain usage was detected in all patients analyzed. No clear-cut relation was observed between TCRVbeta modulation after transplantation and clinical outcome. In some cases modulations appeared to concur with observed immunological events (clinically and/or in-vitro).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005313     DOI: 10.1016/s0966-3274(00)00008-3

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  1 in total

1.  Monitoring the T-cell receptor repertoire at single-clone resolution.

Authors:  Hendrik P J Bonarius; Frank Baas; Ester B M Remmerswaal; René A W van Lier; Ineke J M ten Berge; Paul P Tak; Niek de Vries
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.